279
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Formulation and Characterization of Glibenclamide and quercetin-loaded Chitosan Nanogels Targeting Skin Permeation

ORCID Icon, , , , , , , , , ORCID Icon & show all
Pages 281-293 | Received 20 Mar 2019, Accepted 18 Apr 2019, Published online: 16 May 2019
 

Abstract

Aim: Our aim was to develop and characterize a nanogel formulation containing both glibenclamide and quercetin and to explore the permeation profile of this combination. Methods: Drug-loaded nanogel was prepared by ionic gelation. In addition, optimum encapsulation efficiencies of glibenclamide and quercetin were also obtained. The average nanoparticle size at optimum conditions was determined by Zetasizer. Results: The particle size of the nanogel was found to be 370.4 ± 4.78 nm with a polydispersity index of 0.528 ± 0.04, while the λ potential was positive in a range of 17.6 to 24.8 mV. The percentage cumulative drug release also showed favorable findings. Conclusion: The chitosan nanogel could be a potential alternative for delivering glibenclamide and quercetin through skin.

Financial & competing interests disclosure

This research was supported by a grant from the International Medical University (IMU), Malaysia (Project ID No-BP I-01-14 (31)2017). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Author contributions

DK Chellappan, NJ Yee and BJ Kaur: Laboratory work and writing article; G Gupta, K Dua and M Gulati: Study Design; J Panneerselvam, J Chellian and T Madheswaran: Statistical analysis; S Satija and M Mehta: Proof reading. All authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.